摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-(methoxycarbonyl)quinoline 1-oxide | 1374258-80-6

中文名称
——
中文别名
——
英文名称
7-(methoxycarbonyl)quinoline 1-oxide
英文别名
methyl 1-oxidoquinolin-1-ium-7-carboxylate
7-(methoxycarbonyl)quinoline 1-oxide化学式
CAS
1374258-80-6
化学式
C11H9NO3
mdl
——
分子量
203.197
InChiKey
HUKGAIBUMOKLHZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    371.6±34.0 °C(Predicted)
  • 密度:
    1.24±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    51.8
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    7-(methoxycarbonyl)quinoline 1-oxide三氟甲磺酸酐 、 sodium hydroxide 作用下, 以 乙醇二氯甲烷 为溶剂, 反应 16.17h, 生成 2-(Propan-2-ylamino)quinoline-7-carboxylic acid
    参考文献:
    名称:
    [EN] NOVEL ACC INHIBITORS
    [FR] NOUVEAUX INHIBITEURS DE L'ACC
    摘要:
    A compound having the structures: Formulae (Ia) or (Ib) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein; R selected from the group consisting of H, C1-C6alkyl, C1-C6alkoxy and -(CH2)m-W, where W is C3-C8cycloalkyl, bicycloalkyl, bridged bicycloalkyl, phenyl,, 5- or 6-membered heteroaryl or heterocyclic containing one, two or three heteroatoms selected from the group consisting of N, S and O atoms; wherein each of said alkyl, cycloalkyl, alkoxy, heterocyclic, phenyl, naphthyl or heteroaryl may be unsubstituted or substituted by phenyl, halo, cyano, deuterium, hydroxy, C1-C6alkyl, C1-C6alkoxy, -SO2-R', - CONR'R", NR'COR", -NR'CONR'R", -NR'CO2R", -(CH2)n-SO2-R', -NHSO2-R', -NR"SO2-R', - SO2NR'R", NR'R" or SR' where R' and R'' are independently H, C1-C6alkyl or C3-C8cycloalkyl; R1selected from the group consisting of phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing one, two, three or four heteroatoms selected from the group consisting of N, S and O atoms; and, a 9- or 10-membered bicyclic aryl, heteroaryl or heterocyclic containing one, two or three heteroatoms selected from the group consisting of N, S and O atoms; wherein each of said phenyl, naphthyl, aryl, heterocyclic, or heteroaryl may be unsubstituted or substituted by halo, cyano, deuterium, hydroxy, C1-C6alkyl, C1-C6alkoxy, phenyl, -SO2-R', -CONR'R", NR'COR", -NR'CONR'R", -NR'CO2R", -(CH2)n-SO2-R', -NHSO2-R', -NR"SO2-R, -SO2NR'R", P(O)R'R", Formula (Ic), or NR'R"' or SR' where R' and R'' are independently H, C1-C6alkyl or C3-C8cycloalkyl; and,mandnare independently 0, 1, 2 or 3. The invention also relates to pharmaceutically acceptable salts of these compounds and to pharmaceutically acceptable solvates thereof; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly acne.
    公开号:
    WO2024023727A1
  • 作为产物:
    描述:
    7-溴喹啉1,3-双(二苯基膦)丙烷 、 palladium diacetate 、 间氯过氧苯甲酸 作用下, 以 二氯甲烷二甲基亚砜 为溶剂, 70.0 ℃ 、1.38 MPa 条件下, 反应 19.0h, 生成 7-(methoxycarbonyl)quinoline 1-oxide
    参考文献:
    名称:
    [EN] TEAD INHIBITORS AND USES THEREOF
    [FR] INHIBITEURS DE TEAD ET LEURS UTILISATIONS
    摘要:
    本申请涉及式(I')的化合物,其药学上可接受的组合物以及使用它们的方法。式I'的化合物是TEAD抑制剂,在癌症治疗中有用。
    公开号:
    WO2022204452A1
点击查看最新优质反应信息

文献信息

  • N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS
    申请人:Griffith David A.
    公开号:US20120108619A1
    公开(公告)日:2012-05-03
    The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R 1 , R 2 and R 3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    这项发明提供了化合物的化学式(I)或其药用可接受的盐;其中G是R1,R2和R3如本文所述;以及其药物组合物;以及在治疗受乙酰辅酶A羧化酶抑制调节的动物疾病、状况或紊乱中的使用。
  • TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS
    申请人:Biswas Kaustav
    公开号:US20130157996A1
    公开(公告)日:2013-06-20
    Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    公式I的化合物可用作TRPM8的拮抗剂。这些化合物在治疗许多TRPM8介导的疾病和病症方面非常有用,并可用于制备用于治疗此类疾病和病症的药物和制剂。此类疾病的示例包括但不限于偏头痛和神经病性疼痛。公式I的化合物具有以下结构:其中变量的定义在此提供。
  • N1/N2-lactam acetyl-CoA carboxylase inhibitors
    申请人:Griffith David A.
    公开号:US08859773B2
    公开(公告)日:2014-10-14
    The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    本发明提供了一种公式(I)的化合物或其药学上可接受的盐;其中G为R1,R2和R3如本文所述;其药物组成物;以及在治疗动物中由乙酰辅酶A羧化酶酶抑制调节的疾病,状况或障碍中使用它的用途。
  • TRPM8 antagonists and their use in treatments
    申请人:Chen Jian J.
    公开号:US08710043B2
    公开(公告)日:2014-04-29
    Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    式I的化合物可作为TRPM8拮抗剂使用。这些化合物可用于治疗多种TRPM8介导的疾病和症状,并可用于制备治疗此类疾病和症状的药物和制剂。这些疾病的例子包括但不限于偏头痛和神经病性疼痛。式I的化合物具有以下结构:其中变量的定义在此提供。
  • [EN] TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS<br/>[FR] ANTAGONISTES DE TRPM8 ET LEUR UTILISATION DANS DES TRAITEMENTS
    申请人:AMGEN INC
    公开号:WO2012177893A3
    公开(公告)日:2013-06-13
查看更多